Lymphoma, Malignant Hematology, Drug Development, Transplant & Cellular Therapy, and other medical news & views. Physician ≠ Provider
San Antonio, TX
Joined December 2012
- Tweets4.9K
- Following1.5K
- Followers5.2K
- Likes416
Great to see my friend and former @MedicalCollege colleague Saurabh Chhabra @Chhabra_mayo presenting at #ASCO2026. Exciting data showing good activity of etentamig even after prior BCMA-targeted therapy in MM
Tim Fenske retweeted
🙌🎊 Kudos to co-chairs @UCCancerCenter, @SoniSmithMD, @timfenske & @SitemanCenter, Dr Neha Mehta-Shah, for a GREAT 2️⃣3️⃣rd annual #Chicago Lymphoma Symposium last weekend.
💗🙏 And a heartfelt THANK YOU to all of the wonderful #lymphoma expert speakers for a highly fulfilling 2 days together with >200 attendees.
➡️🗓️ And it is never too early planning for 2027! See our Website: bioascend.com/chicago-lympho…
#IUCLS2026 #Lymphoma #CME
@VaniamGroup
@RWJBarnabas @RutgersCancer
Thank you all for a successful and engaging #IUCLS2026 and be sure and save the date for #IUCLS2027 on April 9-10, 2027!
Tim Fenske retweeted
The United States has spent EIGHT TRILLION DOLLARS fighting and policing in the Middle East. Thousands of our Great Soldiers have died or been badly wounded. Millions of people have died on the other side. GOING INTO THE MIDDLE EAST IS THE WORST DECISION EVER MADE.....
Anyone who has worked with me on inpatient service knows that the Anion Gap is one of my favorite lab tests. So many things it can help diagnose… So imagine how happy I was to meet Dr Emmett, widely credited with popularizing the use of the AG in modern medicine!
Tim Fenske retweeted
RW pola outcomes by Hans COO @CCR_AACR
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R LBCL. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerr…
Tim Fenske retweeted
Michelangelo’s Pietà recreated with drones over St Peter’s at the Vatican last night
Tim Fenske retweeted
CONGRESS | #SOHO2025 | PRESENTATION
Timothy S. Fenske @timfenske, Sarah Cannon Cancer Institute, discusses methods and applications for MRD in front-line and R/R #MantleCellLymphoma settings, including prognostication after treatment, a clinical trial endpoint, surveillance tool, and a trigger for pre-emptive therapy.
Follow our live feed for more updates: loom.ly/rBZZxmc
#Lymphoma #lymsm #MedicalCongress
Tim Fenske retweeted
Ide-cel and Cilta-cel for PCL. N=34, median PFS/OS with ide-cel: 6/9 months; median PFS/OS with cilta cel: 19/>23 months #bmtsm #mmsm @GliceidaGalarzaMD @BloodPortfolio ashpublications.org/bloodadv…
Tim Fenske retweeted
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.
Tim Fenske retweeted
At the 2nd annual #HOPLive, Drs. @timfenske, Jasmine Zain, Alejandro Sica, Swaminathan Iyer, and @MKD_BMT tackled the most pressing unanswered questions in T-cell #lymphoma research and clinical practice.
Watch here ➡️ buff.ly/MT2nITJ
Tim Fenske retweeted
DISEASES ERADICATED OR DECIMATED BY SCIENCE:
1. Chickenpox
2. Diphtheria
3. Measles
4. Pertussis
5. Pneumococcal Infection
6. Polio
7. Tetanus
8. Typhoid
9. Yellow Fever
10. Smallpox
DISEASES ERADICATED OR DECIMATED BY RFK JR. OR PRAYER:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Tim Fenske retweeted
Correspondence: Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma nej.md/4lS7kfe
#Hematology
ALT Clinical and radiologic characteristics of the three patients
Tim Fenske retweeted
Editing is too funny 😂
Before moderating the aggressive NHL panel discussion at #HOPLive, Dr. @MediHumdani sends the audience into laughter telling the story of his travel fiasco. We’re glad you made it to lead this important talk!
Stay tuned for the full-length session➡️ bloodcancerstoday.com/page/t…
Tim Fenske retweeted
🎸🎼🎹🥁Hear the walk-up songs for the mini-symposium on #mantlecell lymphoma.
We were happy to invite @cityofhope Dr @LymphClinician, @HMHNewJersey Dr Lori Leslie & @SarahCannonDocs @timfenske.
🧭🧭 Many varied options for untreated & relapsed disease!
@SoniSmithMD #IUCLS2025
Tim Fenske retweeted
Just out @BloodJournal :
Outcome of #CART therapy for #burkitt #lymphoma.
Another great internatioal collaboration led by @LauraSamplesMD
@fredhutch @uwmnewsroom
ashpublications.org/blood/ar…
Tim Fenske retweeted
🚨🚨Join us in Chicago, April 4 & 5 for the 22nd Annual International Ultmann Chicago Lymphoma Symposium (bioascend.com/chicago-lympho…).
➡️➡️In addition to "Mini-Symposiums" on #DLBCL, Mantle cell, #HRQL & #Genomic Diagnostics, we're thrilled to have Dr Nancy Bartlett as our Keynote!
Tim Fenske retweeted
I'm concerned that the recent @statnews piece re: decline of #BMT by @angRchen could be misleading to the public. Adding some context for consideration in the thread 🧵below: statnews.com/2024/12/24/bone…
